GlassScriptPhysician profile
Glen Douglas Hooker
NPI 1043235864
$10,849.37
in general payments reported to CMS, 2019-2025
24 companies · $373 in 2025
The $373 reported for 2025 was more than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,669 · 2020: $30.38 · 2021: $2,280 · 2022: $1,691 · 2023: $568 · 2024: $238 · 2025: $373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $902 · Travel and Lodging: $277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $901.90 |
| Travel and Lodging | $276.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $9,171.59 | 2019-2025 | |
| Cook Biotech Incorporated | $442.11 | 2023 | Biodesign, Oasis |
| Medtronic, INC. | $278.53 | 2022-2025 | Signia, Ligasure |
| Micro-Tech Endoscopy USA, INC. | $182.06 | 2019 | |
| Acera Surgical, INC. | $101.85 | 2025 | Restrata Wound Matrix |
| Axonics, INC. | $72.82 | 2021-2024 | Axonics |
| Baxter Healthcare | $70.20 | 2019-2021 | |
| Ethicon US, LLC | $51.94 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $47.79 | 2025 | Rebyota |
| Innovation Technologies INC | $45.74 | 2023 | Irrisept |
| Shire North American Group INC | $42.92 | 2019 | |
| Thd America, INC. | $40.18 | 2023-2024 | |
| Braintree Laboratories, INC. | $36.81 | 2023-2024 | Suflave |
| Tela Bio, INC. | $34.81 | 2022-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Covidien LP | $32.56 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Activ Surgical, INC. | $30.58 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.38 | 2020 | |
| Davol INC. | $28.32 | 2023 | Phasix Mesh |
| Integra Lifesciences Corporation | $25.04 | 2024 | Integra, Surgimend, Omnigraft |
| Acell, INC. | $18.52 | 2019 | |
| Medtronic USA, INC. | $18.07 | 2019 | |
| Concordia Pharmaceuticals INC. | $16.20 | 2019 | |
| Polynovo North America LLC | $15.43 | 2024 | Novosorb Btm |
| Smith+Nephew, INC. | $14.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glen Hooker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.